Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype.

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) have been recently derived and are used for basic research, cardiotoxicity assessment, and phenotypic screening. However, the hiPS-CM phenotype is dependent on their derivation, age, and culture conditions, and there is disagreement as to what constitutes a functional hiPS-CM. The aim of the present study is to characterize the temporal changes in hiPS-CM phenotype by examining five determinants of cardiomyocyte function: gene expression, ion channel functionality, calcium cycling, metabolic activity, and responsiveness to cardioactive compounds. Based on both gene expression and electrophysiological properties, at day 30 of differentiation, hiPS-CMs are immature cells that, with time in culture, progressively develop a more mature phenotype without signs of dedifferentiation. This phenotype is characterized by adult-like gene expression patterns, action potentials exhibiting ventricular atrial and nodal properties, coordinated calcium cycling and beating, suggesting the formation of a functional syncytium. Pharmacological responses to pathological (endothelin-1), physiological (IGF-1), and autonomic (isoproterenol) stimuli similar to those characteristic of isolated adult cardiac myocytes are present in maturing hiPS-CMs. In addition, thyroid hormone treatment of hiPS-CMs attenuated the fetal gene expression in favor of a more adult-like pattern. Overall, hiPS-CMs progressively acquire functionality when maintained in culture for a prolonged period of time. The description of this evolving phenotype helps to identify optimal use of hiPS-CMs for a range of research applications.

[1]  D. Cokkinos,et al.  Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. , 2007, European journal of endocrinology.

[2]  Lior Gepstein,et al.  Myocardial regeneration strategies using human embryonic stem cell-derived cardiomyocytes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[3]  I. Klein,et al.  Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes. , 2001, Journal of molecular and cellular cardiology.

[4]  C. Xinaris,et al.  Time-dependent changes in the expression of thyroid hormone receptor alpha 1 in the myocardium after acute myocardial infarction: possible implications in cardiac remodelling. , 2007, European journal of endocrinology.

[5]  C. Mummery,et al.  Prospects for pluripotent stem cell‐derived cardiomyocytes in cardiac cell therapy and as disease models , 2009, Journal of cellular biochemistry.

[6]  Peter Sartipy,et al.  The application of human embryonic stem cell technologies to drug discovery. , 2007, Drug discovery today.

[7]  S. Pikkarainen,et al.  Endothelin-1-specific Activation of B-type Natriuretic Peptide Gene via p38 Mitogen-activated Protein Kinase and Nuclear ETS Factors* , 2003, The Journal of Biological Chemistry.

[8]  Robert Passier,et al.  Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. , 2009, Trends in pharmacological sciences.

[9]  F. Brosius,et al.  Glucose Uptake and Glycolysis Reduce Hypoxia-induced Apoptosis in Cultured Neonatal Rat Cardiac Myocytes* , 1999, The Journal of Biological Chemistry.

[10]  P. Razeghi,et al.  Return to the fetal gene program protects the stressed heart: a strong hypothesis , 2007, Heart Failure Reviews.

[11]  LimorZwi,et al.  Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells , 2009 .

[12]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors , 2008 .

[13]  K L Kolaja,et al.  Opportunities for Use of Human iPS Cells in Predictive Toxicology , 2011, Clinical pharmacology and therapeutics.

[14]  R. Hajjar,et al.  Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. , 1998, The Journal of clinical investigation.

[15]  Michael R. Bristow,et al.  Regulation of Thyroid Hormone Receptor Isoforms in Physiological and Pathological Cardiac Hypertrophy , 2001, Circulation research.

[16]  O. Hudlická,et al.  Postnatal growth of the heart and its blood vessels. , 1996, Journal of vascular research.

[17]  H. Reuter,et al.  Properties and modulation of cardiac calcium channels. , 1986, The Journal of experimental biology.

[18]  D. Cokkinos,et al.  Thyroid hormone and phenotypes of cardioprotection , 2004, Basic Research in Cardiology.

[19]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[20]  J. Winer,et al.  Phenylephrine, endothelin, prostaglandin F2alpha' and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro. , 1998, Endocrine.

[21]  U. Hoppe,et al.  Distinct regulation of cardiac If current via thyroid receptors alpha1 and beta1 , 2009, Pflügers Archiv - European Journal of Physiology.

[22]  Jürgen Hescheler,et al.  Human Pluripotent Stem Cell-Derived Cardiomyocytes: Response to TTX and Lidocain Reveals Strong Cell to Cell Variability , 2012, PloS one.

[23]  B. A. Harder,et al.  Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes , 1997, Journal of Molecular Medicine.

[24]  David Tweedie,et al.  Differentiation of Pluripotent Embryonic Stem Cells Into Cardiomyocytes , 2002, Circulation research.

[25]  Jarno M. A. Tanskanen,et al.  Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions—a comparison of multiple cell lines , 2009, Annals of medicine.

[26]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[27]  A. Consiglio,et al.  Generation of cardiomyocytes from new human embryonic stem cell lines derived from poor-quality blastocysts. , 2008, Cold Spring Harbor symposia on quantitative biology.

[28]  J. Hyllner,et al.  Differentiation of Human Embryonic Stem Cells to Cardiomyocytes for In Vitro and In Vivo Applications , 2010, Stem Cell Reviews and Reports.

[29]  M. Roselle Abraham,et al.  Dedifferentiation and Proliferation of Mammalian Cardiomyocytes , 2010, PloS one.

[30]  Sean P. Palecek,et al.  Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells , 2009, Circulation research.

[31]  R. Stewart,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[32]  Divya Rajamohan,et al.  Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. , 2010, Biochemical Society transactions.

[33]  M. Morrison,et al.  Patenting human pluripotent cells: balancing commercial, academic and ethical interests. , 2010, Human reproduction.

[34]  Jeffrey Robbins,et al.  Principles of genetic murine models for cardiac disease. , 2007, Circulation.

[35]  E. Marbán,et al.  Beta-adrenergic stimulation of calcium channels occurs by potentiation of high-activity gating modes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Xinaris,et al.  Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"? , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[37]  Moorman Af,et al.  A molecular approach towards the understanding of early heart development: an emerging synthesis. , 1992 .

[38]  W. Dillmann Cardiac hypertrophy and thyroid hormone signaling , 2009, Heart Failure Reviews.

[39]  Ofer Binah,et al.  Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes. , 2007, Journal of electrocardiology.

[40]  J. Daut,et al.  Long-chain fatty acids increase basal metabolism and depolarize mitochondria in cardiac muscle cells. , 2002, American journal of physiology. Heart and circulatory physiology.

[41]  Anders Lindahl,et al.  Human embryonic stem cells: current technologies and emerging industrial applications. , 2008, Critical reviews in oncology/hematology.

[42]  J. Winer,et al.  Phenylephrine, endothelin, prostaglandin F2α, and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro, and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro , 1998, Endocrine.

[43]  Ondrej Juhasz,et al.  Embryonic stem cells and cardiomyocyte differentiation: phenotypic and molecular analyses , 2005, Journal of cellular and molecular medicine.

[44]  Elina Minami,et al.  Cardiogenic Differentiation and Transdifferentiation of Progenitor Cells , 2008, Circulation research.

[45]  H. Jongsma,et al.  Beta-, not alpha-adrenergic stimulation enhances conduction velocity in cultures of neonatal cardiomyocytes. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[46]  G. Lopaschuk,et al.  Energy Metabolic Phenotype of the Cardiomyocyte During Development, Differentiation, and Postnatal Maturation , 2010, Journal of cardiovascular pharmacology.

[47]  Lawrence Buja,et al.  Change in Expression of Heart Carnitine Palmitoyltransferase I Isoforms with Electrical Stimulation of Cultured Rat Neonatal Cardiac Myocytes (*) , 1996, The Journal of Biological Chemistry.

[48]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[49]  田中 智文,et al.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes , 2012 .

[50]  H. Yaku,et al.  Hyperthyroidism causes mechanical insufficiency of myocardium with possibly increased SR Ca2+-ATPase activity. , 2003, The Japanese journal of physiology.

[51]  K. Plath,et al.  Reprogrammed Mouse Fibroblasts Differentiate into Cells of the Cardiovascular and Hematopoietic Lineages , 2008, Stem cells.

[52]  M. Donath,et al.  Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  E. Woodcock,et al.  Cardiomyocytes structure, function and associated pathologies. , 2005, The international journal of biochemistry & cell biology.

[54]  Teodor Veres,et al.  Cell culture chips for simultaneous application of topographical and electrical cues enhance phenotype of cardiomyocytes. , 2009, Lab on a chip.

[55]  M. Rao,et al.  Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. , 2008, Stem cells and development.

[56]  Eric D. Adler,et al.  Specification of multipotential cardiovascular progenitor cells during embryonic stem cell differentiation and embryonic development. , 2007, Trends in cardiovascular medicine.

[57]  R. Tsien,et al.  Calcium Channel Types in Cardiac Myocytes: Modulation by Dihydropyridines and β‐Adrenergic Stimulation , 1986, Journal of cardiovascular pharmacology.

[58]  C. Xinaris,et al.  Thyroid hormone receptors alpha1 and beta1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion. , 2005, Basic Research in Cardiology.

[59]  P. Kang,et al.  The Insulin-like Growth Factor 1 Receptor Induces Physiological Heart Growth via the Phosphoinositide 3-Kinase(p110α) Pathway* , 2004, Journal of Biological Chemistry.

[60]  S. Yamanaka,et al.  The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. , 2009, Biochemical and biophysical research communications.

[61]  C. Xinaris,et al.  Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications. , 2008, Pharmacology & therapeutics.

[62]  P. Kang,et al.  The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. , 2004, The Journal of biological chemistry.

[63]  B. Thiers Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .

[64]  C. Scott,et al.  Challenges to human embryonic stem cell patents. , 2008, Cell stem cell.

[65]  A. Clerk,et al.  Endothelin signalling in the cardiac myocyte and its pathophysiological relevance. , 2005, Current vascular pharmacology.

[66]  Peter Sartipy,et al.  Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery. , 2009, Current opinion in drug discovery & development.

[67]  篠原 隆司,et al.  Induction of pluripotent stem cell cells from germ cells , 2012 .

[68]  G. Galanopoulos,et al.  Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction , 2010, Molecular and Cellular Biochemistry.

[69]  S. Herzig,et al.  Effects of β2-adrenergic stimulation on single-channel gating of rat cardiac L-type Ca2+ channels. , 1999, American journal of physiology. Heart and circulatory physiology.

[70]  L. Fink,et al.  Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts , 2009, Cell biology international.

[71]  R. Lerch,et al.  Regulation of glucose transporter expression in cardiac myocytes: p38 MAPK is a strong inducer of GLUT4. , 2004, Cardiovascular research.

[72]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[73]  Hideki Uosaki,et al.  Directed and Systematic Differentiation of Cardiovascular Cells From Mouse Induced Pluripotent Stem Cells , 2008, Circulation.

[74]  C. Xinaris,et al.  Thyroid hormone receptors α1 and β1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion , 2005, Basic Research in Cardiology.

[75]  K. Rakušan,et al.  Immediate postnatal rat heart development modified by abdominal aortic banding: Analysis of gene expression , 1996, Molecular and Cellular Biochemistry.

[76]  David B. Resnik,et al.  The Commercialization of Human Stem Cells: Ethical and Policy Issues , 2004, Health Care Analysis.